secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001193125-22-246364
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics appoints Katharine Knobil to Board, amends bylaws
---------------------------------------------------------------------

- Dr. Katharine Knobil appointed to newly created Board seat; term expires at 2025 annual meeting.
- Knobil will serve on R&D Committee; qualifies as independent director.
- She receives option for 30,000 shares vesting over 3 years, annual retainer $39,000 prorated.
- Board approved Second Amended and Restated Bylaws with enhanced shareholder proposal requirements and emergency procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312522246364/0001193125-22-246364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312522246364/d400254d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-246364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer